Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance

Annals of the New York Academy of Sciences

Volumn 1417, Issue 1, 2016, Pages 35-56

  Contreras Kallens, Pamina ^a   Terraza, Claudia ^a   Oyarce, Karina ^a   Gajardo, Tania ^a   Campos Mora, Mauricio ^a   Barroilhet, María Teresa ^a   Álvarez, Carla ^a   Fuentes, Ricardo ^a   Figueroa, Fernando ^a   Khoury, Maroun ^a,b,c   Pino Lagos, Karina ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b Chilean Consortium for Regenerative Medicine   (Chile)

^c Chilean Consortium for Regenerative Medicine ^*  (Chile)

Author keywords

Immunosuppression; MSC; T cells; Therapy; Tolerance; Transplantation

Indexed keywords

5' NUCLEOTIDASE; HLA DR ANTIGEN;

B LYMPHOCYTE; CELL MIGRATION; CELL POPULATION; CLINICAL OUTCOME; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MEMORY T LYMPHOCYTE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOCYTE; NONHUMAN; PHENOTYPE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE;

EID: 85023177574     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13364     Document Type: Review

References (178)

1. Brent, L. 2016. Transplantation tolerance—a historical introduction. Immunology 147: 267–268.
2. Brent, L. 1997. The discovery of immunologic tolerance. Hum. Immunol. 52: 75–81.
3. Sachs, D.H. 2011. Transplant tolerance: bench to bedside— 26th annual Samuel Jason Mixter Lecture. Arch. Surg. 146: 501–505.
4. Lakkis, F.G. 2003. Transplantation tolerance: a journey from ignorance to memory. Nephrol. Dial. Transplant. 18: 1979–1982.
5. Walsh, P.T., T.B. Strom & L.A. Turka. 2004. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity 20: 121–131.
6. Waldmann, H. 2010. Tolerance: an overview and perspectives. Nat. Rev. Nephrol. 6: 569–576.
7. Ezzelarab, M. & A.W. Thomson. 2011. Tolerogenic dendritic cells and their role in transplantation. Semin. Immunol. 23: 252–263.
8. Wood, K.J., A. Bushell & J. Hester 2012. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12: 417– 430.
9. Kirk, A.D., N.A. Turgeon & N.N. Iwakoshi. 2010. B cells and transplantation tolerance. Nat. Rev. Nephrol. 6: 584– 593.
10. Ruiz, P., P. Maldonado, Y. Hidalgo, et al. 2013. Transplant tolerance: new insights and strategies for long-term allograft acceptance. Clin. Dev. Immunol. 2013: 210506.
11. Castro-Manrreza, M.E. & J.J. Montesinos. 2015. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J. Immunol. Res. 2015: 394917
12. Chen, X., M.A. Armstrong & G. Li. 2006. Mesenchymal stem cells in immunoregulation. Immunol. Cell Biol. 84: 413–421.
13. Friedenstein, A.J., S. Piatetzky, II & K.V. Petrakova. 1966. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16: 381–390.
14. da Silva Meirelles, L., P.C. Chagastelles & N.B. Nardi. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119(Pt 11): 2204–2213.
15. Caplan, A.I. & J.E. Dennis. 2006. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 98: 1076–1084.
16. Lv, F.J., R.S. Tuan, K.M. Cheung & V.Y. Leung. 2014. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32: 1408–1419.
17. Alcayaga-Miranda, F., J. Cuenca, P. Luz-Crawford, et al. 2015. Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells. Stem Cell Res. Ther. 6: 32.
18. Horwitz, E.M., K. Le Blanc, M. Dominici, et al. 2005. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393–395.
19. Mahmood, A., D. Lu, M. Lu & M. Chopp. 2003. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 53: 697–702 discussion 702–703.
20. + CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156: 149–160.
21. Stagg, J. & J. Galipeau. 2013. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr. Mol. Med. 13: 856–867.
22. Spaggiari, G.M., A. Capobianco, H. Abdelrazik, et al. 2008. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111: 1327–1333.
23. Duffy, M.M., J. Pindjakova, S.A. Hanley, et al. 2011. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41: 2840–2851.
24. Kim, J. & P. Hematti. 2009. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 37: 1445–1453.
25. Maggini, J., G. Mirkin, I. Bognanni, et al. 2010. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 5: e9252.
26. Zhang, Q.Z., W.R. Su, S.H. Shi, et al. 2010. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 28: 1856–1868.
27. Francois, M., R. Romieu-Mourez, M. Li & J. Galipeau. 2012. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20: 187–195.
28. Cutler, A.J., V. Limbani, J. Girdlestone & C.V. Navarrete. 2010. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J. Immunol. 185: 6617–6623.
29. +-derived and monocyte-derived dendritic cells. J. Immunol. 177: 2080–2087.
30. Djouad, F., L.M. Charbonnier, C. Bouffi, et al. 2007. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25: 2025–2032.
31. Spaggiari, G.M., H. Abdelrazik, F. Becchetti & L. Moretta. 2009. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113: 6576–6583.
32. English, K., F.P. Barry & B.P. Mahon. 2008. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 115: 50– 58.
33. Zhang, B., R. Liu, D. Shi, et al. 2009. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113: 46–57.
34. Jiang, X.X., Y. Zhang, B. Liu, et al. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120– 4126.
35. Laranjeira, P., J. Gomes, S. Pedreiro, et al. 2015. Human bone marrow-derived mesenchymal stromal cells differentially inhibit cytokine production by peripheral blood monocytes subpopulations and myeloid dendritic cells. Stem Cells Int. 2015: 819084.
36. Aggarwal, S. & M.F. Pittenger. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815–1822.
37. Aldinucci, A., L. Rizzetto, L. Pieri, et al. 2010. Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J. Immunol. 185: 5102–5110.
38. Ramasamy, R., C.K. Tong, H.F. Seow, et al. 2008. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell. Immunol. 251: 131–136.
39. Deans, R.J. & A.B. Moseley. 2000. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28: 875– 884.
40. Le Blanc, K., L. Tammik, B. Sundberg, et al. 2003. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57: 11–20.
41. Krampera, M., L. Cosmi, R. Angeli, et al. 2006. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386–398.
42. Petrini, I., S. Pacini, M. Petrini, et al. 2009. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur. J. Clin. Invest. 39: 813–818.
43. Krampera, M., S. Glennie, J. Dyson, et al. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722–3729.
44. Djouad, F., P. Plence, C. Bony, et al. 2003. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837–3844.
45. Di Nicola, M., C. Carlo-Stella, M. Magni, et al. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838–3843.
46. Glennie, S., I. Soeiro, P.J. Dyson, et al. 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105: 2821–2827.
47. Giuliani, M., M. Fleury, A. Vernochet, et al. 2011. Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One 6: e19988.
48. Guo, Z., C. Zheng, Z. Chen, et al. 2009. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 39: 2840–2849.
49. Meisel, R., A. Zibert, M. Laryea, et al. 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619–4621.
50. Nasef, A., N. Mathieu, A. Chapel, et al. 2007. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84: 231–237.
51. + regulatory T cells. Stem Cells 26: 212–222.
52. Sato, K., K. Ozaki, I. Oh, et al. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228–234.
53. Lepelletier, Y., S. Lecourt, A. Renand, et al. 2010. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev. 19: 1075–1079.
54. Su, J., X. Chen, Y. Huang, et al. 2014. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 21: 388–396.
55. Moriggl, R., D.J. Topham, S. Teglund, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10: 249–259.
56. Munn, D.H., E. Shafizadeh, J.T. Attwood, et al. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189: 1363–1372.
57. Metz, R., S. Rust, J.B. Duhadaway, et al. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by d-1-methyl-tryptophan. Oncoimmunology 1: 1460–1468.
58. Bottcher, M., A.D. Hofmann, H. Bruns, et al. 2016. Mesenchymal stromal cells disrupt mTOR-signaling and aerobic glycolysis during T-cell activation. Stem Cells 34: 516–521.
59. Tordjman, R., Y. Lepelletier, V. Lemarchandel, et al. 2002. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol. 3: 477–482.
60. Kikutani, H. & A. Kumanogoh 2003. Semaphorins in interactions between T cells and antigen-presenting cells. Nat. Rev. Immunol. 3: 159–167.
61. Rasmusson, I., K. Le Blanc, B. Sundberg & O. Ringden. 2007. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65: 336–343.
62. Nguyen, T.M., A. Arthur, J.D. Hayball & S. Gronthos. 2013. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. Stem Cells Dev. 22: 2751–2764.
63. Gu, Y.Z., Q. Xue, Y.J. Chen, et al. 2013. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Hum. Immunol. 74: 267–276.
64. Cambiaggi, C., M.T. Scupoli, T. Cestari, et al. 1992. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. Immunogenetics 36: 117–120.
65. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323–330.
66. Stacey, D.W. 2003. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15: 158–163.
67. Pagano, M., R. Pepperkok, F. Verde, et al. 1992. Cyclin A is required at two points in the human cell cycle. EMBO J. 11: 961–971.
68. Pianta, S., P. Bonassi Signoroni, I. Muradore, et al. 2015. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev. 11: 394–407.
69. Patel, S.A., J.R. Meyer, S.J. Greco, et al. 2010. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J. Immunol. 184: 5885–5894.
70. + T-cell activation by inducing IL-10-producing Th1 cells. Stem Cells Dev. 22: 1063–1075.
71. Bettelli, E., Y. Carrier, W. Gao, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235– 238.
72. Luz-Crawford, P., D. Noel, X. Fernandez, et al. 2012. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 7: e45272.
73. Ge, W., J. Jiang, J. Arp, et al. 2010. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 90: 1312–1320.
74. Fallarino, F., U. Grohmann, C. Vacca, et al. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9: 1069–1077.
75. Ghannam, S., J. Pene, G. Moquet-Torcy, et al. 2010. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185: 302–312.
76. Martin-Orozco, N., P. Muranski, Y. Chung, et al. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787–798.
77. Qu, X., X. Liu, K. Cheng, et al. 2012. Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp. Hematol. 40: 761–770.
78. Carrion, F., E. Nova, C. Ruiz, et al. 2010. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19: 317–322.
79. Zhou, K., H. Zhang, O. Jin, et al. 2008. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell. Mol. Immunol. 5: 417–424.
80. + T cells. Immunity 30: 155–167.
81. Lexberg, M.H., A. Taubner, A. Forster, et al. 2008. Th memory for interleukin-17 expression is stable in vivo. Eur. J. Immunol. 38: 2654–2664.
82. Rafei, M., P.M. Campeau, A. Aguilar-Mahecha, et al. 2009. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182: 5994–6002.
83. Liu, X., S. Ren, X. Qu, et al. 2015. Mesenchymal stem cells inhibit Th17 cells differentiation via IFN-γ-mediated SOCS3 activation. Immunol. Res. 61: 219–229.
84. Laurence, A., C.M. Tato, T.S. Davidson, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371–381.
85. + regulatory T cells. J. Immunol. 178: 280–290.
86. Qi, H., G. Chen, Y. Huang, et al. 2015. Foxp3-modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats. J. Transl. Med. 13: 274.
87. Maccario, R., A. Moretta, A. Cometa, et al. 2005. Human mesenchymal stem cells and cyclosporin A exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol. Blood Marrow Transplant. 11: 1031–1032.
88. Saldanha-Araujo, F., F.I. Ferreira, P.V. Palma, et al. 2011. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res. 7: 66–74.
89. Lee, J.J., H.J. Jeong, M.K. Kim, et al. 2014. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal. 10: 357–365.
90. Cai, S.F., X. Cao, A. Hassan, et al. 2010. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 115: 1669–1677.
91. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742.
92. Carrier, Y., J. Yuan, V.K. Kuchroo & H.L. Weiner 2007. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J. Immunol. 178: 172–178.
93. Andolfi, G., G. Fousteri, M. Rossetti, et al. 2012. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells. Mol. Ther. 20: 1778–1790.
94. Taylor, P.A., C.J. Lees & B.R. Blazar. 2002. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493–3499.
95. Luz-Crawford, P., F. Djouad, K. Toupet, et al. 2016. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells 34: 483–492.
96. Mougiakakos, D., R. Jitschin, C.C. Johansson, et al. 2011. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117: 4826–4835.
97. Liotta, F., R. Angeli, L. Cosmi, et al. 2008. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26: 279–289.
98. Del Papa, B., P. Sportoletti, D. Cecchini, et al. 2013. Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. Eur. J. Immunol. 43: 182–187.
99. + hemopoietic pro- genitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J. Immunol. 180: 1598–1608.
100. + regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res. Ther. 6: 19.
101. Rashedi, I., A. Gomez-AristizAbal, X.H. Wang, et al. 2016. TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via notch signaling. Stem Cells 35: 265–275.
102. Opitz, C.A., U.M. Litzenburger, C. Lutz, et al. 2009. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27: 909– 919.
103. + regulatory T (Treg) cells via androgen TGF-β interaction. J. Appl. Biomed. 13: 263–271.
104. – precursors. Am. J. Transplant. 4: 1614–1627.
105. Gieseke, F., J. Bohringer, R. Bussolari, et al. 2010. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116: 3770–3779.
106. Liu, G.Y., Y. Xu, Y. Li, et al. 2013. Secreted galectin-3 as a possible biomarker for the immunomodulatory potential of human umbilical cord mesenchymal stromal cells. Cytotherapy 15: 1208–1217.
107. Sioud, M. 2011. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand. J. Immunol. 73: 79–84.
108. Baum, L.G., D.P. Blackall, S. Arias-Magallano, et al. 2003. Amelioration of graft versus host disease by galectin-1. Clin. Immunol. 109: 295–307.
109. Wang, F., W. He, J. Yuan, et al. 2008. Activation of Tim-3–Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl. Immunol. 19: 12–19.
110. Gieseke, F., A. Kruchen, N. Tzaribachev, et al. 2013. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur. J. Immunol. 43: 2741–2749.
111. Ungerer, C., P. Quade-Lyssy, H.H. Radeke, et al. 2014. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 23: 755–766.
112. Kim, S.N., H.J. Lee, M.S. Jeon, et al. 2015. Galectin-9 is involved in immunosuppression mediated by human bone marrow-derived clonal mesenchymal stem cells. Immune Netw. 15: 241–251.
113. Zhu, C., A.C. Anderson, A. Schubart, et al. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245–1252.
114. Cedeno-Laurent, F. & C.J. Dimitroff 2012. Galectin-1 research in T cell immunity: past, present and future. Clin. Immunol. 142: 107–116.
115. Luz-Crawford, P., G. Tejedor, A.L. Mausset-Bonnefont, et al. 2015. Glucocorticoid-induced leucine zipper governs the therapeutic potential of mesenchymal stem cells by inducing a switch from pathogenic to regulatory Th17 cells in a mouse model of collagen-induced arthritis. Arthritis Rheumatol. 67: 1514–1524.
116. Yang, N., B. Baban, C.M. Isales & X.M. Shi. 2015. Crosstalk between bone marrow-derived mesenchymal stem cells and regulatory T cells through a glucocorticoid-induced leucine zipper/developmental endothelial locus-1-dependent mechanism. FASEB J. 29: 3954–3963.
117. – T cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12: 666– 669.
118. Liu, Q., H. Zheng, X. Chen, et al. 2015. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(–) regulatory T cells. Cell. Mol. Immunol. 12: 708–718.
119. – T-suppressor cells in living donor liver transplant recipients. Hepatobiliary Pancreat. Dis. Int. 8: 241– 246.
120. Klaus, G., K. Mostert, B. Reckzeh & T.F. Mueller. 2003. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 76: 1719–1724.
121. Bestard, O., E. Crespo, M. Stein, et al. 2013. Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am. J. Transplant. 13: 1880–1890.
122. Heeger, P.S., N.S. Greenspan, S. Kuhlenschmidt, et al. 1999. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J. Immunol. 163: 2267–2275.
123. Augustine, J.J., D.S. Siu, M.J. Clemente, et al. 2005. Pretransplant IFN-gamma ELISPOTs are associated with posttransplant renal function in African American renal transplant recipients. Am. J. Transplant. 5: 1971–1975.
124. Di Ianni, M., B. Del Papa, M. De Ioanni, et al. 2008. Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol. 36: 309–318.
125. Turner, D.L., C.L. Gordon & D.L. Farber. 2014. Tissue-resident T cells, in situ immunity and transplantation. Immunol. Rev. 258: 150–166.
126. Turner, D.L., K.L. Bickham, J.J. Thome, et al. 2014. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7: 501–510.
127. Comoli, P., F. Ginevri, R. Maccario, et al. 2008. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol. Dial. Transplant. 23: 1196–1202.
128. Liu, O., J. Xu, G. Ding, et al. 2013. Periodontal ligament stem cells regulate B lymphocyte function via programmed cell death protein 1. Stem Cells 31: 1371–1382.
129. Rosado, M.M., M.E. Bernardo, M. Scarsella, et al. 2015. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 24: 93–103.
130. Franquesa, M., F.K. Mensah, R. Huizinga, et al. 2015. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 33: 880– 891.
131. Asari, S., S. Itakura, K. Ferreri, et al. 2009. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37: 604–615.
132. Rafei, M., J. Hsieh, S. Fortier, et al. 2008. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112: 4991–4998.
133. Corcione, A., F. Benvenuto, E. Ferretti, et al. 2006. Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367–372.
134. Augello, A., R. Tasso, S.M. Negrini, et al. 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35: 1482–1490.
135. Schena, F., C. Gambini, A. Gregorio, et al. 2010. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 62: 2776–2786.
136. Xue, Q., X.Y. Luan, Y.Z. Gu, et al. 2010. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev. 19: 27–38.
137. Hermankova, B., A. Zajicova, E. Javorkova, et al. 2016. Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells. Immunobiology 221: 129–136.
138. Tabera, S., J.A. Perez-Simon, M. Diez-Campelo, et al. 2008. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haemato-logica 93: 1301–1309.
139. Chen, Y., J. Yang, H.J. Zhang, et al. 2016. Sca-1(+) mesenchymal stromal cells inhibit splenic marginal zone B lymphocytes commitment through Caspase-3. Cell Biol. Int. 40: 549–559.
140. Traggiai, E., S. Volpi, F. Schena, et al. 2008. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26: 562–569.
141. Reichardt, P., B. Dornbach, S. Rong, et al. 2007. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 110: 1519–1529.
142. Odendahl, M., H. Mei, B.F. Hoyer, et al. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105: 1614–1621.
143. Guo, Y., K.H. Chan, W.H. Lai, et al. 2013. Human mesenchymal stem cells upregulate CD1dCD5(+) regulatory B cells in experimental autoimmune encephalomyelitis. Neu-roimmunomodulation 20: 294–303.
144. Healy, M.E., R. Bergin, B.P. Mahon & K. English. 2015. Mesenchymal stromal cells protect against caspase 3-mediated apoptosis of CD19(+) peripheral B cells through contact-dependent upregulation of VEGF. Stem Cells Dev. 24: 2391– 2402.
145. Newell, K.A., A. Asare, A.D. Kirk, et al. 2010. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120: 1836–1847.
146. Sagoo, P., E. Perucha, B. Sawitzki, et al. 2010. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120: 1848– 1861.
147. + regulatory B cells producing interleukin 10. Leukemia 29: 636–646.
148. de Masson, A., J.D. Bouaziz, H. Le Buanec, et al. 2015. CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood 125: 1830–1839.
149. Bartholomew, A., C. Sturgeon, M. Siatskas, et al. 2002. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30: 42–48.
150. Casiraghi, F., N. Azzollini, P. Cassis, et al. 2008. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181: 3933–3946.
151. Wang, Y., A. Zhang, Z. Ye, et al.2009. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant. Proc. 41: 4352–4356.
152. Ding, Y., D. Xu, G. Feng, et al. 2009. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 58: 1797–1806.
153. Ge, W., J. Jiang, M.L. Baroja, et al. 2009. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am. J. Transplant. 9: 1760–1772.
154. Casiraghi, F., N. Azzollini, M. Todeschini, et al. 2012. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am. J. Transplant. 12: 2373–2383.
155. + T cell subsets. Cell. Immunol. 253: 23–30.
156. Kong, Q.F., B. Sun, S.S. Bai, et al. 2009. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J. Neuroimmunol. 207: 83–91.
157. Nemeth, K., A. Keane-Myers, J.M. Brown, et al. 2010. Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl. Acad. Sci. U.S.A. 107: 5652–5657.
158. Akiyama, K., C. Chen, D. Wang, et al. 2012. Mesenchymal-stem-cell-induced immunoregulation involves FAS-FAS- ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10: 544–555. ligand-/FAS-mediated
159. Inoue, S., F.C. Popp, G.E. Koehl, et al. 2006. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81: 1589–1595.
160. Chen, X., Y. Gan, W. Li, et al. 2014. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis. 5: e1009.
161. Sudres, M., F. Norol, A. Trenado, et al. 2006. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176: 7761–7767.
162. Polchert, D., J. Sobinsky, G. Douglas, et al. 2008. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38: 1745–1755.
163. Zhao, K., R. Lou, F. Huang, et al. 2015. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 21: 97–104.
164. Te Boome, L.C., C. Mansilla, L.E. van der Wagen, et al. 2015. Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia 29: 1839–1846.
165. Levine, J.E., B.R. Logan, J. Wu, et al. 2012. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 119: 3854– 3860.
166. Yin, F., M. Battiwalla, S. Ito, et al. 2014. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells 32: 1278–1288.
167. Jitschin, R., D. Mougiakakos, L. Von Bahr, et al. 2013. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 31: 1715–1725.
168. Ball, L.M., M.E. Bernardo, H. Roelofs, et al. 2013. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br. J. Haematol. 163: 501– 509.
169. Calkoen, F.G., C.M. Jol-van der Zijde, M.L. Mearin, et al. 2013. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response. Biol. Blood Marrow Transplant. 19: 1590–1599.
170. Batorov, E.V., E.Y. Shevela, M.A. Tikhonova, et al. 2015. Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas. Cell. Immunol. 297: 80–86.
171. Shipounova, I.N., N.A. Petinati, A.E. Bigildeev, et al. 2014. Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry 79: 1363– 1370.
172. Franquesa, M., M.J. Hoogduijn, M.E. Reinders, et al. 2013. Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: lessons learned from first clinical trials. Transplantation 96: 234–238.
173. Perico, N., F. Casiraghi, E. Gotti, et al. 2013. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl. Int. 26: 867– 878.
174. Tan, J., W. Wu, X. Xu, et al. 2012. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307: 1169–1177.
175. Peng, Y., M. Ke, L. Xu, et al. 2013. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95: 161–168.
176. Sánchez-Guijo, F., T. Caballero-Velázquez, O. López-Villar, et al. 2014. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 20: 1580–1585.
177. Vanikar, A., H.L. Trivedi, A. Kumar, et al. 2014. Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells help safe minimization of immunosuppression in renal transplantation—single center experience. Ren. Fail. 36: 1376–1384.
178. Reinders, M., J. Futer, H. Roelofs, et al. 2013. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl. Med. 2: 107–111.